Neumora Therapeutics (NMRA) Stock Price, News & Analysis

Company Overview

Neumora Therapeutics (NASDAQ: NMRA) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of treatments for central nervous system (CNS) disorders. The company’s research platform integrates computational biology, medicinal chemistry and high-throughput screening to accelerate the identification of novel small molecules and biologic candidates. Neumora’s focus spans mood disorders, neuropathic pain, epilepsy and movement disorders, addressing significant unmet medical needs in psychiatric and neurological care.

At the core of Neumora’s pipeline are several lead programs: an investigational therapy targeting synaptic modulation for treatment-resistant depression and suicidality; a small molecule designed to modulate excitatory pathways in refractory epilepsy; and additional assets aimed at neuropathic pain and Parkinson’s disease. Each program is supported by biomarker-driven clinical trials and preclinical studies, leveraging translational science to optimize patient selection and demonstrate proof of concept.

Founded in 2019 as Day One Biopharma and rebranded to Neumora Therapeutics in 2021, the company is headquartered in Boston, Massachusetts, with research collaborations across North America and Europe. Neumora has established partnerships with leading academic centers and contract research organizations to advance its CNS portfolio. The company’s global footprint aims to facilitate multi-regional clinical trials and streamline regulatory interactions in key markets.

Neumora’s leadership team combines deep expertise in neuroscience drug development and operations. Douglas Cole serves as President and Chief Executive Officer, bringing over two decades of experience in biopharma strategy and R&D. The executive team includes seasoned professionals in clinical development, regulatory affairs and chemistry, manufacturing and controls (CMC). Under this leadership, Neumora is positioned to translate scientific innovation into new therapies for patients with debilitating neurological and psychiatric conditions.

Key Stats

• Today's Range: $1.80 to $1.98
• 50-Day Range: $0.62 to $1.85
• 52-Week Range: $0.61 to $17.19
• Volume: 1.39 million shs
• Average Volume: 1.61 million shs
• Market Capitalization: $305.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.14
• Consensus Rating: Hold

Neumora Therapeutics Stock Analysis - MarketRank™

Neumora Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 560th out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Hold

Consensus Rating

Neumora Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on 3 buy ratings, 5 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Neumora Therapeutics has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Neumora Therapeutics are expected to grow in the coming year, from ($1.61) to ($1.54) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Neumora Therapeutics is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neumora Therapeutics is -1.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Neumora Therapeutics has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

16.13% of the float of Neumora Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Neumora Therapeutics has a short interest ratio ("days to cover") of 9.6.

Change versus previous month

Short interest in Neumora Therapeutics has recently decreased by 27.65%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neumora Therapeutics does not currently pay a dividend.

Dividend Growth

Neumora Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

16.13% of the float of Neumora Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Neumora Therapeutics has a short interest ratio ("days to cover") of 9.6.

Change versus previous month

Short interest in Neumora Therapeutics has recently decreased by 27.65%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: 0.59

News Sentiment

Neumora Therapeutics has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Neumora Therapeutics this week, compared to 8 articles on an average week.

Search Interest

Only 2 people have searched for NMRA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Neumora Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Neumora Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

26.80% of the stock of Neumora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

47.65% of the stock of Neumora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NMRA Stock Analysis - Frequently Asked Questions

How have NMRA shares performed this year?

Neumora Therapeutics' stock was trading at $10.60 at the start of the year. Since then, NMRA shares have decreased by 82.2% and is now trading at $1.89.

How were Neumora Therapeutics' earnings last quarter?

Neumora Therapeutics, Inc. (NASDAQ:NMRA) issued its earnings results on Monday, May, 12th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.40) by $0.02.
Read the conference call transcript.

When did Neumora Therapeutics IPO?

Neumora Therapeutics (NMRA) raised $250 million in an initial public offering on Friday, September 15th 2023. The company issued 14,710,000 shares at $17.00 per share.

How do I buy shares of Neumora Therapeutics?

Shares of NMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Neumora Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Neumora Therapeutics investors own include Grayscale Ethereum Trust (ETH) (ETHE), VALE (VALE), Paycom Software (PAYC), Clean Energy Fuels (CLNE), Centrus Energy (LEU), uniQure (QURE) and ThredUp (TDUP).

Company Calendar

• Last Earnings: 5/12/2025
• Today: 7/23/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NMRA
• CIK: 1885522
• Web: neumoratx.com
• Phone: 857-760-0900
• Fax: N/A
• Employees: 108
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Neumora Therapeutics: $7.14
• High Price Target: $18.00
• Low Price Target: $1.00
• Potential Upside/Downside: +277.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.22
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.61)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$243.79 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -84.79%
• Return on Assets: -77.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.98
• Quick Ratio: 8.98

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.78 per share
• Price / Book: 1.06

Miscellaneous

• Outstanding Shares: 161,750,000
• Free Float: 118,400,000
• Market Cap: $305.71 million
• Optionable: Optionable
• Beta: 2.75